---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-006188"
form_type: "8-K"
ticker: "AYTU"
cik: "0001385818"
company_name: "AYTU BIOPHARMA, INC"
filed_at: "2023-04-19T23:59:59+00:00"
generated_at: "2026-06-16T23:29:14.270465+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "medium"
source: SEC EDGAR
---

# Aytu BioPharma explores strategic alternatives and financing to address liquidity; SEC inquiry ongoing

## Summary
- Preliminary discussions underway for potential strategic transactions and financing options.
- Company cites ongoing liquidity needs; no assurance that any deal will materialize.
- Equity financings would provide liquidity but could be dilutive to existing stockholders.
- SEC inquiry active regarding proposed restatements; timing of restatement and Q2 10-Q filing uncertain.

## SEC filing metadata
- accession: 0001558370-23-006188
- form_type: 8-K
- ticker: AYTU
- cik: 0001385818
- company_name: AYTU BIOPHARMA, INC
- filed_at: 2023-04-19T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: medium
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1385818/000155837023006188/0001558370-23-006188-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1385818/000155837023006188/aytu-20230419x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-006188
- JSON: https://secwatch.observer/filing/0001558370-23-006188.json
- Plain text: https://secwatch.observer/filing/0001558370-23-006188.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.